In a filing, Orchestra BioMed Holdings Inc revealed its 10% Owner RTW INVESTMENTS, LP acquired Company’s shares for reported $0.15 million on Apr 30 ’25. In the deal valued at $2.99 per share,49,900 shares were bought. As a result of this transaction, RTW INVESTMENTS, LP now holds 8,306,063 shares worth roughly $27.91 million.
Then, RTW INVESTMENTS, LP bought 50,000 shares, generating $126,500 in total proceeds. Upon buying the shares at $2.53, the 10% Owner now owns 8,256,163 shares.
Before that, Hochman David P bought 4,000 shares. Orchestra BioMed Holdings Inc shares valued at $18,640 were divested by the insider at a price of $4.66 per share. As a result of the transaction, Hochman David P now holds 579,498 shares, worth roughly $1.95 million.
BTIG Research initiated its Orchestra BioMed Holdings Inc [OBIO] rating to a Buy in a research note published on March 20, 2025; the price target was $12. A number of analysts have revised their coverage, including Barclays’s analysts, who began to cover the stock in early January with a ‘”an Overweight”‘ rating. H.C. Wainwright began covering OBIO with “Buy” recommendation on August 22, 2024. B. Riley Securities started covering the stock on July 25, 2024. It rated OBIO as “a Buy”.
Price Performance Review of OBIO
On Tuesday, Orchestra BioMed Holdings Inc [NASDAQ:OBIO] saw its stock fall -0.59% to $3.36. Over the last five days, the stock has gained 0.60%. Orchestra BioMed Holdings Inc shares have fallen nearly -16.00% since the year began. Nevertheless, the stocks have fallen -57.03% over the past one year. While a 52-week high of $8.87 was reached on 01/02/25, a 52-week low of $2.37 was recorded on 05/07/25.
Levels Of Support And Resistance For OBIO Stock
The 24-hour chart illustrates a support level at 3.22, which if violated will result in even more drops to 3.08. On the upside, there is a resistance level at 3.49. A further resistance level may holdings at 3.62.
The most recent change occurred on January 19, 2024 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $14 price target.
